# Amisulpride in Schizophrenic Acute Phase Patients

> **NCT00436371** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 50 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Amisulpride

## Key facts

- **NCT ID:** NCT00436371
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2008-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436371, "Amisulpride in Schizophrenic Acute Phase Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00436371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*